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Background. Tacrolimus has been used as a primary 
immunosuppressive agent in adult and pediatric renal 
transplant recipients, with reasonable outcomes. 
Methods. Between December 14, 1989 and December 
31, 1996, 82 pediatric renal transplantations alone 
were performed under tacrolimus-based immunosup-
pression without induction anti-lymphocyte antibody 
therapy. Patients undergoing concomitant or prior 
liver and/or intestinal transplantation were not in-
cluded in the analysis. The mean recipient age was 
10.6±5.2 years (range: 0.7-17.9). Eighteen (22%) cases 
were repeat transplantations, and 6 (7%) were in pa-
tients with panel-reactive antibody levels over 40%. 
Thirty-four (41%) cases were with living donors, and 
48 (590/0) were with cadaveric donors. The mean donor 
age was 27.3±14.6 years (range: 0.7-50), and the mean 
cold ischemia time in the cadaveric cases was 26.5±8.8 
hr. The mean number of lILA matches and mismatches 
was 2.8±1.2 and 2.9±1.3; there were five (6%) O-Ag 
mismatches. The mean follow-up was 4.0±0.2 years. 
Results. The 1- and 4-year actuarial patient survival 
was 99% and 94%. The 1- and 4-year actuarial graft 
survival was 98% and 84%. The mean serum creatinine 
was 1.1±O.5 mgldl, and the corresponding calculated 
creatinine clearance was 88±25 mJlminl1.73 m 2 • A total 
of 66% of successfully transplanted patients were 
withdrawn from prednisone. In children who were 
withdrawn from steroids, the mean standard devia-
tion height scores (Z-score) at the time of transplanta-
tion and at 1 and 4 years were -2.3±2.0, -1.7±1.0, and 
+0.36±1.5. Eighty-six percent of successfully trans-
planted patients were not taking anti.hypertensive 
medications. The incidence of acute rejection was 44%; 
between December 1989 and December 1993, it was 
63%, and between January 1994 and December 1996, it 
was 23% (P=0.OOO3). The incidence of steroid-resistant 
rejection was 5%. The incidence of delayed graft func-
tion was 5%, and 2% of patients required dialysis 
within 1 week of transplantation. The incidence of 
cytomegalovirus was 13%; between December 1989 
and December 1992, it was 17%, and between January 
1993 and December 1996, it was 12%. The incidence of 
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early Epstein-Barr virus-related posttransplant Iym. 
phoproliferative disorder (PTLD) was 9%; between De-
cember 1989 and December 1992, it was 17%, and be-
tween January 1993 and December 1996, it was 4%. All 
ofthe early PTLD cases were treated successfully with 
temporary cessation of immunosuppression and insti-
tution of antiviral therapy, without patient or graft 
loss. 
Conclusions. These data demonstrate the short- and 
medium-term efficacy of tacrolimus-based immuno· 
suppression in pediatric renal transplant recipients, 
with reasonable patient and graft survival, routine 
achievement of steroid and anti-hypertensive medica· 
tion withdrawal, gratifying increases in growth, and, 
with further experience, a decreasing incidence of 
both rejection and PTLD. 
The efficacy of tacrolimus is a primary immunosuppressive 
agent in adult renal transplant recipients has been estab-
lished in a number of single- and multicenter trials (1-10). In 
pediatric renal transplant recipients, however, there is rela-
tively less experience regarding its use as a primary agent 
(11-20)_ We have previously reported on the use oftacrolimus 
in pediatric renal transplantation (11-17), and have found it 
to be associated with reasonable patient and graft survival 
and an ability to withdraw steroids in the majority of suc-
cessfully transplant patients. This has been associated with 
improved growth, particularly in preadolescent children. In 
this report, we present an update of our experience, and 
discuss strategies to optimize immunosuppression under tao 
crolimus-based therapy and minimize the incidence of ad-
verse events_ 
PATIENTS AND METHODS 
Between December 14, 1989, and December 31, 1996, 81 pediatric 
recipients received 82 kidney transplantations only under tacroli-
mus-based immunosuppression at the Children's Hospital of Pitts-
burgh (Table 1). Patients undergoing concomitant or previous liver 
and/or intestinal transplantation were not included in this analysis. 
The mean recipient age was 10.6::5.2 years (range: 0.7-17.9). Seven 
(9%) were under 2 years ofage, 10 (12%) were between 2 and 5 years, 
and 65 (79%) were over 5 years of age. Sixty-four (78%) were under-
going their first transplant. and 18 (22%) were undergoing their 
second (n= 11), third (n=5), or fourth (n=2) transplant. Ten of these 
18 had received their previous transplants elsewhere. Six (7%) pa-
tients had panel-reactive antibody levels over 40%; all were under-
going repeat transplantation. There were 7 (9%) Mrican-American 
and 75 (93%) Caucasian recipients. The causes of end-stage renal 
disease are listed in Table 2. 
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TABLE 1. Recipient/donor demographics 
n=82 (81 patients) 
Recipient age 
<2yr 
2-5 yr 
>5yr 
First transplant 
Repeat transplant 
Second transplant 
Third transplant 
Fourth transplant 
moAa~4M% 
PRA<40% 
Donor age 
Living donor 
Cadaveric donor 
~Ryr 
Cold ischemia time 
HLA match 
HLA mismatch 
O-Ag mismatch 
10.6±5.2 yr (range: 0.7-17.9) 
7 (9%) 
10 (12%) 
65 (79%) 
64(78%) 
18 (22%) 
11 (13%) 
5 (6%) 
2 (2%) 
6 (7%) 
76 (93%) 
27.3±14.6 yr (range: 0.7-50) 
34 (41%): 31 parents, 1 sister, 
1 grandmother, 1 adoptive 
father 
48 (59%) 
9 (19%) 
26.5±8.8 hr (range: 9.3-4) 
2.8±1.2 
2.9±1.3 
5 (6%) 
a PRA, panel-reactive antibody. 
TABLE 2. Causes of end-stage renal disease 
Obstructive uropathy 
Congenital dysplasia 
Membranoproliferative glomerular nephritis 
Focal segmental glomerulosclerosis 
Hemolytic-uremic syndrome 
Polycystic kidney disease 
Prune belly syndrome 
Congenital hypoplasia 
Ureteral reflux 
Chronic glomerulonephritis 
Interstitial nephritis 
Pyelonephritis 
Alport's syndrome 
Cystinosis 
Hereditary nephritis 
Other 
Undetermined 
14 (17%) 
12 (15%) 
8(10%) 
7(9%) 
4(5%) 
4(5%) 
3 (4%) 
3 (4%) 
3(4%) 
2(2%) 
2(2%) 
2(2%) 
2(2%) 
2(2%) 
2(2%) 
9 (11%) 
3(4%) 
The mean donor age was 27.3±14.6 years (range: 0.7-50>. Forty-
eight (59%) cases were with cadaveric donors, 9 (19%) of which were 
single (n=6) or en bloc (n=3) pediatric donors 5 years of age or 
younger; the recipients of these pediatric kidneys were all over 10 
years of age. The mean cold ischemia time was 26.5=:8.8 hr (range 
9.3-45.2). 
There were 34 (41%) living donors-31 parents. 1 sister, 1 grand-
mother. and 1 adoptive father. 
The mean number ofHLA matches and mismatches was 2.8=:1.2 
and 2.9=:1.3. respectively; there were five ES~F O-antigen mismatch 
cases. 
Immunosuppression was with tacrolimus and steroids. as de-
scribed previously (16. 17). Induction antilymphocyte antibody was 
not used. Twenty-two percent of patients received azathioprine. My-
cophenolate mofetil was not used initially in any patient. 
The patient survival rate was calculated from the date of kidney 
transplantation until death, and the graft survival rate was calcu-
lated from the date of kidney transplantation until graft failure. 
repeat transplantation. or patient death. Survival curves wee gen-
erated using the Kaplan-Meier (product limit) method and were 
compared using the log-rank (Mantel-Cox) test. All tests were two-
tailed. A P-value less than 0.05 was considered statistically signifi-
cant. 
Until June 1994, when tacrolimus was approved by the U.S. Food 
and Drug Administration. all transplants were performed under a 
protocol approved by the Human Rights Committee of the Children's 
Hospital of Pittsburgh. 
The mean follow-up was 4.0=:0.2 (SE) years. 
RESULTS 
The 1- and 4-year actuarial patient survival rates were 
99% and 94% (Table 3, Fig. 1). Four patients died, 3-38 
months after transplantation, of pancreatitis (3 and 15 
months), fungal sepsis (15 months), and unclear etiology, on 
dialysis (38 months; 18 months after allograft nephrectomy). 
The 1- and 4-year actuarial graft survival rates were 98% 
and 84%. Fourteen patients lost their allografts, 1 week to 58 
months after transplantation, to rejection (n=5), recurrent 
disease (n=5), pancreatitis (n=2), fungal sepsis (n=I), and 
noncompliance (n = 1). Patients undergoing repeat transplan-
tation and sensitized patients with panel-reactive antibody 
levels over 40% had statistically inferior graft survival rates. 
Recipients of cadaveric kidneys from donors 5 years of age or 
younger had graft survival rates similar to those seen in 
recipients of cadaveric kidneys from donors over 5 years of 
age. 
At most recent follow-up, the mean serum creatinine was 
1.1±0.5 mg/dl, and the calculated creatinine clearance was 
88±25 mVminl1.73 m2 • The blood urea nitrogen was 23±8 
mg/dl. 
The mean tacrolimus dose was 0.18:::0.12 mg/kg/day, and 
the mean level was 9.9±4.6 ng/ml by whole blood IMx. The 
TABLE 3. Resultsa 
Follow-up 4.0±0.2 yr 
n 1yr 4yr 
Overall actuarial patient 81 99% 94% 
survival 
Overall actuarial graft 82 98% 84% 
survival 
First transplant 64 100% 90% P<0.02 
Repeat transplant 18 89% 66% 
Cadaveric 48 96% 86% P=NS 
Living donor 34 100% 81% 
PRA <40% 76 99% 87% P<0.03 
PRA ~4M% 6 86% 57% 
Recipient <2 yr 7 100% 100% P=NS 
Recipient 2-5 yr 10 90% 60% 
Recipient >5 yr 65 98% 86% 
Cadaveric donor ~R yr 9 100% 89% P=NS 
Cadaveric donor >5 yr 39 97% 84% 
Serum creatinine 1.1 =:0.5 mgldl 
Calculated creatinine 88=:25 mUminl1.73 m2 
clearance 
BUN 23±8 mgldl 
Off steroids 66% 
Off antihypertensive 86% 
medications 
Serum cholesterol 155=:31 mgldl 
.. BUN. blood urea D1trogen: PRA. panel-reactive antibody. 
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FIGURE 1. Actuarial patient and graft survival. 
initial dose was 0.05-0.10 mg/kglday as a continuous intra-
venous infusion, followed by a gradual transition to oral 
tacrolimus 0.15 mg/kg twice daily, with target levels of20-25 
ng/ml for the first 2 weeks, 15-20 ng/ml by 1 month, 10-15 
ng/ml by 3 months, and 5-9 ng/ml chronically. 
The incidence of delayed graft function was 5%; 2% of 
patients required dialysis during the first week after trans-
plantation (Table 4). 
The incidence of acute rejection and steroid-resistant re-
jection was 44% and 5%; between December 1989 and De-
cember 1993, the incidence of acute rejection was 63%, and 
between January 1994 and December 1996, it was 23% 
(P=0.0003). This change reflected our success at maintaining 
the high early target levels (20-25 ng/mD, by gradually re-
ducing the intravenous dosage of tacrolimus while oral ta-
crolimus was being introduced. 
The incidence of cytomegalovirus, either symptomatic dis-
ease or asymptomatic infection, was 13% and did not change 
appreciably over this time period. 
The incidence of early Epstein-Barr virus (EBV*)-related 
posttransplant lymphoproliferative disorder (PTLD) was 9%; 
between December 1989 and December 1992, it was 17% 
(5/29 cases), and between January 1993 and December 1996, 
* Abbreviations: EBV, Epstein-Barr virus; PTDM. posttransplant 
diabetes mellitus; PTLD, posttransplant lymphoproliferative disor-
der. 
TABLE 4. Adverse events 
Delayed graft function 
Dialysis in first week 
Rejection 
12189-12193 
1/94-12196 
Steroid-resistant rejection 
Cytomegalovirus 
Early PTLD 
12189-12192 
1193-12196 
Late lymphoma 
PTDM 
Initial 
Final 
5% 
2% 
44% 
63% 
23% (P=0.0003) 
5% 
13% 
9% 
17% 
4% 
2.4% 
9% 
1'C 
it was 4% (2153 cases). All cases were treated with temporary 
discontinuation of immunosuppression and intravenous gan-
cyclovir, without mortality or short-term graft loss; one pa-
tient lost his allograft to chronic rejection 3 years later. In 
addition, there were two late cases of lymphoma, occurring 
3.8 and 4.3 years after transplantation; both patients re-
ceived chemotherapy with cyclophosphamide, vincristine, 
methotrexate, adriamycin, etoposide, cytosine arabinoside. 
and prednisone (one patient also required central nervous 
system radiation), with complete eradication of the lympho-
mas in both cases. Both patients were restarted on low-dose 
tacrolimus 5 months after completion of chemotherapy, and 
both have maintained allograft function 7.2 and 6.4 years 
after transplantation. 
Insulin-dependent posttransplant diabetes mellitus 
(PTDM) was seen initially in 9% of successfully transplanted 
patients. After reduction of tacrolimus and steroid dosing, 
the final incidence was 1%. 
At most recent follow-up, 66% of successfully transplanted 
patients were off steroids (Table 3). The mean steroid dose 
was O.04±O.09 mg/kg/day; in the patients still taking pred-
nisone, it was O.17±O.11 mg/kg/day. Standard deviation 
scores (Z-scores) at the time of transplantation and at 1 and 
4 years after transplantation were -2.3±2.0, -1.7±1.1, and 
+O.08±2.5 for all patients, and -2.3±2.0, -1.7±1.0, and 
+O.36±1.5 in patients taken off prednisone (Table 5). Eight-
six percent of patients were off antihypertensive medica-
tions, and the mean serum cholesterol level was 155±31 
mg/dl (Table 3). 
DISCUSSION 
This report extends our previous work demonstrating the 
efficacy oftacrolimus as a primary immunosuppressive agent 
in pediatric kidney transplantation. Reasonable 1- and 
4-year actuarial patient and graft survival rates of 99% and 
94%, and 98% and 84%, respectively, have been achieved. 
Two-thirds of the successfully transplanted recipients were 
able to discontinue steroids, and in many cases achieved 
normal growth. Eighty-six percent of the patients were able 
to discontinue antihypertensive medications, and the mean 
serum cholesterol level was normal. The incidence of delayed 
graft function was low, and, with increasing experience, the 
incidence of acute rejection has fallen to 23%, with a very low 
rate of steroid-resistant rejection. Maintaining high tacroli-
mus levels during the first 2 weeks has played an important 
role in decreasing the rate of acute rejection. 
In spite of these favorable outcomes, there have been very 
TABLE 5. Standard deviation scores tZ-scoresJ 
Time of transplantation 
lyr 
4yr 
Time of transplantation 
1yr 
4yr 
Time of transplantatIOn 
lyr 
4 yr 
-2.3::2.0 
-1.7::1.1 
+0.08::2.5 
Off steroids On steroids 
-2.3::2.0 
-1.7:=1.0 -2.0::1.1 
... 0.36:: 1.5 -0.6::2.9 
,012 yr >12 yr 
-2.3:=2.2 -2.2::1.7 
-1.5:: 1.0 -1.9:= 1.3 
-0.84:=3.0 -1.6:= 1.3 
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few published reports from other centers regarding the use of 
tacrolimus as a primary immunosuppressive agent in pedi-
atric kidney recipients. There have been two reports, from 
the University of Minnesota (18) and Johns Hopkins (19), 
with excellent short-term patient and graft survival statis-
tics, and one abstract from Hannover (20) describing less 
favorable outcomes in three repeat transplant recipients who 
had developed recurrent hemolytic uremic syndrome under 
cyclosporine with their first transplants. This paucity of re-
ports from other centers is probably related to the early high 
incidence of viral complications, especially PTLD, reported 
by our program (13, 15, 16), and, to a lesser extent, the 
incidence ofPTDM (21). It is worth noting that the observed 
incidence of early PTLD has declined markedly, as more 
experience has been gained with tacrolimus. There are sev-
eral reasons that have contributed to this reduced incidence. 
The first has been an aggressive policy of tapering both 
tacrolimus and steroids, with the goal of discontinuing ste-
roids and maintaining low chronic trough levels of 5-9 ng/ml 
(16, 17). The second has involved prophylaxis, in the EBV-
seropositive donorlEBV-seronegative recipient, with gancy-
clovir and cytomegalovirus hyperimmune globulin, both of 
which are known to have a significant anti-EBV activity (22, 
23). The third has been, in recent years, improved monitoring 
using EBV serology and polymerase chain reaction testing, to 
detect primary EBV infections before they become PTLD 
(24). Finally, once patients have been tapered to a stable 
tacrolimus dose, it is generally unnecessary to raise the dose; 
children do not outgrow their tacrolimus requirement. Thus, 
it should be possible to reduce to a minimum the incidence of 
PTLD. 
Tacrolimus-induced PTDM is another important adverse 
event, but is readily reversible with gradual dosage reduction 
of tacrolimus and tapering or even discontinuing prednisone 
(25,26). Virtually all cases ofPTDM in the pediatric patients 
have been transient. 
The other two important side effects of tacrolimus, neph-
rotoxicity and neurotoxicity, have been well described and 
are generally reversible with dosage reduction (27-32). They 
are not different qualitatively or quantitatively from those 
described with cyclosporine-based regimens. 
The attainment of normal growth has been an important, 
but not always achievable goal of pediatric renal transplan-
tation. The only group of pediatric patients who have come 
close to this goal are those who have been able to discontinue 
steroids. and tacrolimus is the first agent that can allow 
routine steroid withdrawal. 
There are significant potential benefits associated with 
tacrolimus-based immunosuppression in children, and, with 
increasing experience. the incidence of adverse events. such 
as rejection and PTLD, can be reduced. The expanded use of 
tacrolimus in pediatric kidney transplantation should, there-
fore. be given serious consideration by the pediatric nephrol-
ogy and transplant community. 
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A NEW ALLOCATION PLAN FOR RENAL TRANSPLANTATION1 
FRANCIS 1. DELMONICO,2 WILLIAM E. HARMON, MARc 1. LORBER, JANE GoGUEN, HELEN MAli, 
JONATHAN HIMMELFARB, GEORGE LIPKOWITZ, SHAUNEEN VALLIERE, LAURINE Bow, 
EDGAR 1. MILFORD, AND RICHARD J. ROHRER 
Background. A novel plan of renal allograft alloca-
tion has been conducted by United Network for Organ 
Sharing Region 1 transplant centers since September 
3, 1996, based upon lILA matching, time waiting, and 
population distance points. The objectives of this plan 
were to achieve a balance between increasing the op-
portunity of renal transplantation for those patients 
listed with long waiting times and promoting local 
organ donor availability. 
Methods. A single list of candidates was formulated 
for each cadaver donor, assigning a maximum of 8 
points for time waiting, a maximum of 8 points for 
popUlation distance from the donor hospital, and HLA 
points based upon the degree of BIDR mismatch. Ad-
1 Presented at the 24th Annual Meeting of the American Society of 
Transplant Surgeons. May 13-15. 1998. Chicago, 11. 
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Director, New England Organ Bank. One Gateway Center. Newton. 
:-'1A 02458-2803. E-mail: francis_delmonicocwneob.com. 
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ditional points were awarded to a cross-match-nega-
tive patient with a panel-reactive antibody of >80%, 
and to pediatric patients. 
Results. The total number of kidneys transplanted to 
patients who had waited >3 years was 100 (46%), and 
to patients who had waited >2.5-3 years was 29 (13%). 
However, the total number of kidneys transplanted to 
patients with the maximum population distance 
points was only 72 (33%). Thus. although the plan 
achieved a favorable distribution of kidneys to pa-
tients with longer waiting times (nearly 600/0), the 
other, equally important objective of promoting local 
donor availability was not initially accomplished. 
Moreover, minor HLA BIDR differences between the 
donor and the recipient (i.e .• not phenotypically 
matched) were unexpectedly consequential in deter-
mining allocation. 
As a result of these observations, the following adjust-
ments were made in the plan (as of December 3, 1997): a 
maximum of 10 points for population distance. a maxi-
